Advanced search
Publication Cover
Expert Review of Neurotherapeutics Volume 16, 2016 - Issue 10
Submit an article Journal homepage
1,471
Views
14
CrossRef citations to date
0
Altmetric
Drug Profile

Ocrelizumab for the treatment of relapsing-remitting multiple sclerosis

Til MengeDepartment of Neurology, Heinrich-Heine University Düsseldorf, Düsseldorf, Germany;Department of Neurology, LVR-Klinikum Düsseldorf, Düsseldorf, GermanyCorrespondence[email protected]
View further author information
,
Divyanshu DubeyDepartment of Neurology and Neurotherapeutics, UT Southwestern Medical Center, Dallas, TX, USAView further author information
,
Clemens WarnkeDepartment of Neurology, Heinrich-Heine University Düsseldorf, Düsseldorf, GermanyView further author information
,
Hans-Peter HartungDepartment of Neurology, Heinrich-Heine University Düsseldorf, Düsseldorf, GermanyView further author information
&
Olaf StüveDepartment of Neurology and Neurotherapeutics, UT Southwestern Medical Center, Dallas, TX, USA;Neurology Section, VA North Texas Health Care System, Medical Service, Dallas, TX, USAView further author information
Pages 1131-1139 | Received 20 Jul 2016, Accepted 18 Aug 2016, Published online: 01 Sep 2016

Citations (14)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (2)

Ludwig Rasche & Friedemann Paul. (2018) Ozanimod for the treatment of relapsing remitting multiple sclerosis. Expert Opinion on Pharmacotherapy 19:18, pages 2073-2086.
Read now
Francois Grand’Maison, Michael Yeung, Sarah A. Morrow, Liesly Lee, Francois Emond, Brian J. Ward, Pierre Laneuville & Robyn Schecter. (2018) Sequencing of disease-modifying therapies for relapsing–remitting multiple sclerosis: a theoretical approach to optimizing treatment. Current Medical Research and Opinion 34:8, pages 1419-1430.
Read now

Articles from other publishers (12)

Valeriya A. Malko, Gennady N. Bisaga, Mariya P. Topuzova, Ivan K. Ternovykh & Tatyana M. Alekseeva. (2023) COVID-19 Features in Patients with Multiple Sclerosis: Main Approaches to Their Management, Treatment, and Vaccination. Annals of Clinical and Experimental Neurology 17:2, pages 51-60.
Crossref
Rawan Hamdan Alenazy, Mohammed Majed S Abualshamat, Fahad Sh S Dh Alqahs, Abdullah F N Almutairi, Mohammed Khalid Moslih Alharbi, Bandar Mohammad Alkhuraimi, Yahya Abdulrahman Dhamiri, Mohammed Munir Abdullah Alshahrani, Kholoud Mesfer Alshahrani & Mohammed Abdullah Alghamdi. (2021) The Role of Ocrelizumab in Multiple Sclerosis Treatment. Archives Of Pharmacy Practice 12:3, pages 117-120.
Crossref
V.S. Krasnov & Yu.M. Kolontareva. (2021) Siponimod: a new view at the therapy of secondary progressive multiple sclerosis. Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova 121:7, pages 124.
Crossref
Erik EllwardtLeoni RolfesJulia KleinKatrin PapeTobias RuckHeinz WiendlMichael SchroeterFrauke ZippSven G. MeuthClemens WarnkeStefan Bittner. (2020) Ocrelizumab initiation in patients with MS. Neurology Neuroimmunology & Neuroinflammation 7:4.
Crossref
Bodhraj Acharya, Rakeshchandra R. Meka, Shivaprasad H. Venkatesha, Jason R. Lees, Tambet Teesalu & Kamal D. Moudgil. (2020) A novel CNS-homing peptide for targeting neuroinflammatory lesions in experimental autoimmune encephalomyelitis. Molecular and Cellular Probes 51, pages 101530.
Crossref
Keith A Sacco & Roshini S Abraham. (2018) Consequences of B-cell-depleting therapy: hypogammaglobulinemia and impaired B-cell reconstitution. Immunotherapy 10:8, pages 713-728.
Crossref
JASNA JANCIC, BLAŽO NIKOLIC, NIKOLA IVANCEVIC, BORIS HENCIC & JANKO SAMARDŽIC. 2017. Multiple Sclerosis: Perspectives in Treatment and Pathogenesis. Multiple Sclerosis: Perspectives in Treatment and Pathogenesis 39 52 .
Divyanshu DubeyThomas ForsthuberEoin P. FlanaganSean J. PittockOlaf Stüve. (2017) B-cell–targeted therapies in relapsing forms of MS. Neurology Neuroimmunology & Neuroinflammation 4:6.
Crossref
Allen D. DeSena. (2017) Immune-Mediated CNS Diseases: a Review. Current Physical Medicine and Rehabilitation Reports 5:3, pages 134-142.
Crossref
Sean Burnard, Jeannette Lechner-Scott & Rodney J. Scott. (2017) EBV and MS: Major cause, minor contribution or red-herring?. Multiple Sclerosis and Related Disorders 16, pages 24-30.
Crossref
Ai-Lan Nguyen, Melissa Gresle, Tessa Marshall, Helmut Butzkueven & Judith Field. (2017) Monoclonal antibodies in the treatment of multiple sclerosis: emergence of B-cell-targeted therapies. British Journal of Pharmacology 174:13, pages 1895-1907.
Crossref
Clemens Warnke & Hans-Peter Hartung. (2017) Natalizumab-associated progressive multifocal leukoencephalopathy is not preceded by elevated drug concentrations. Multiple Sclerosis Journal 23:7, pages 920-922.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.